Moderator Scott Gottlieb, MD, ended the Oncology Stakeholder Summit, Fall 2015, by asking the panel for closing statements.
Ted Okon, executive director of Community Oncology Alliance, said that one of the biggest things still to be addressed is site neutrality. Although he is encouraged by the Balanced Budget Act—through which, starting in 2017, a visit to a hospital outpatient facility and a visit to a physician’s office will both be paid under the Medicare physician fee schedule—he would like to see a little more legislative work done on the 340B program.
Kavita Patel, MD, MS, referred back to measurements of patient satisfaction, saying that current methods, like consumer assessments and survey tools, are crude and inconsistent. Meanwhile, the private sector continues to innovate in terms of measuring patient satisfaction, but their methods are not being integrated; payment models continue to roll out with mandated requirements for patient satisfaction and patient surveys. Dr Patel said she would like more flexibility in quality metrics, more latitude in clinician performance, and more enforcement with an outcomes-based transparency database.
John L. Fox, MD, MHA, spoke of the developments in the oncology sphere explaining, “Not only do we have the emergence of the oncology care model with CMI, we have new drug therapies especially with the PD-1 and PD-L1 antagonists. We have Medicare now approving advanced care planning and paying physicians and other healthcare providers to talk about what patients’ preferences are and what their priorities and their goals of care are. I think it's an exciting time because the people who will win in this are those who are willing to experiment and collaborate.” Dr Fox would like to have this collaboration across multiple organizations and stakeholders because they will lead the way to more affordable healthcare, and better patient outcomes and experiences.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More